Výsledky vyhledávání - "Erythropoietin receptor activity"

Effects of erythropoietin receptor activity on angiogenesis, tubular injury, and fibrosis in acute kidney injury: a 'U-shaped' relationship

Autor: Ming Chang Hu, Lily Jun Shen Huang, Mingjun Shi, Philip R. Streeter, Kathryn L. McMillan, Yong Ping Zhong, Peng Li, Orson W. Moe, Sachdev S. Sidhu, Nancy Gillings, Maria T. Grompe, Jianfeng Ye, Brianna Flores

Publikováno v: American Journal of Physiology-Renal Physiology. 314:F501-F516

The erythropoietin receptor (EpoR) is widely expressed but its renoprotective action is unexplored. To examine the role of EpoR in vivo in the kidney, we induced acute kidney injury (AKI) by ischemia-reperfusion in mice with different EpoR bioactivit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53a09526dcb1a394a71168461459459d
https://doi.org/10.1152/ajprenal.00306.2017

Zobrazit plný text záznamu

Experimental acute myocardial infarction in rats: HIF-1α, caspase-3, erythropoietin and erythropoietin receptor expression and the cardioprotective effects of two different erythropoietin doses

Autor: Özlem Yavuz, Aysel Guven Bagla, Meltem Ickin, Askin Kaplan, Ertugrul Ercan, Halil Fatih Asgun, Suat Bagla, Feriha Ercan

Publikováno v: Acta Histochemica. 115:658-668

The cardioprotective effects of two different doses of erythropoietin administration were analyzed in rats with experimental myocardial infarction. None, saline, standard-dose (5000Ukg(-1)) and high-dose (10,000Ukg(-1)) of human recombinant erythropo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97b5d70899afbb600d6f0962566863c6
https://doi.org/10.1016/j.acthis.2013.01.005

Zobrazit plný text záznamu

A dose exploration, phase I/II study of administration of continuous erythropoietin receptor activator once every 3 weeks in anemic patients with multiple myeloma receiving chemotherapy

Autor: Ivan Spicka, Anna Dmoszynska, Joseph E. Eid, Janusz Kloczko, Malgorzata Rokicka, Andrzej Hellmann

Publikováno v: Haematologica. 92:493-501

Background and Objectives Continuous erythropoietin receptor activator (C.E.R.A.) is an innovative agent with unique erythropoietin receptor activity and a prolonged half-life, which has the potential for administration at extended dosing intervals.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7b49bcb537debd5153e184a3a29dbae
https://doi.org/10.3324/haematol.10730

Zobrazit plný text záznamu

Regulation of Erythropoietin Receptor Activity in Endothelial Cells by Different Erythropoietin (EPO) Derivatives: An in Vitro Study

Autor: Serena Cuboni, Maria Letizia Trincavelli, Eleonora Da Pozzo, Claudia Martini, Osele Ciampi, Simona Daniele, Maria P. Abbracchio

Publikováno v: International Journal of Molecular Sciences; Volume 14; Issue 2; Pages: 2258-2281
International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 14, Iss 2, Pp 2258-2281 (2013)

In endothelial cells, erythropoietin receptors (EPORs) mediate the protective, proliferative and angiogenic effects of EPO and its analogues, which act as EPOR agonists. Because hormonal receptors undergo functional changes upon chronic exposure to a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5ffb07db00d19080d2c130020792187

Zobrazit plný text záznamu

Pharmacokinetic and pharmacodynamic profiles of subcutaneous administration of continuous erythropoietin receptor activator in lung cancer patients with anemia induced by chemotherapy

Autor: Hideo Kunitoh, Toshiaki Takahashi, Shunichi Negoro, Nobuyuki Yamamoto, Yutaka Nishiwaki, Tomohide Tamura

Continuous erythropoietin receptor activator (C.E.R.A.) is an innovative erythropoiesis-stimulating agent with unique erythropoietin receptor activity and a prolonged half-life. C.E.R.A. is currently in development for the correction of anemia and st

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38938fbaaa15d3b8c6d74555b18e7cee
https://europepmc.org/articles/PMC3406562/

Zobrazit plný text záznamu

Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy

Autor: John A. Glaspy, Paul Mainwaring, Vera Hirsh, Rodryg Ramlau, Joseph E. Eid, Christian Manegold

Publikováno v: Trials
Trials, Vol 8, Iss 1, p 8 (2007)

Background C.E.R.A. (Continuous Erythropoietin Receptor Activator) is an innovative agent with unique erythropoietin receptor activity and prolonged half-life. This study evaluated C.E.R.A. once weekly (QW) or once every 3 weeks (Q3W) in patients wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93d8ada8e4643cc1d88215105b13ce38
https://doi.org/10.1186/1745-6215-8-8

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání